Search Results - "Gill, Joan C"

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A by Mahlangu, Johnny, Kuliczkowski, Kazimierz, Karim, Faraizah Abdul, Stasyshyn, Oleksandra, Kosinova, Marina V., Lepatan, Lynda Mae, Skotnicki, Aleksander, Boggio, Lisa N., Klamroth, Robert, Oldenburg, Johannes, Hellmann, Andrzej, Santagostino, Elena, Baker, Ross I., Fischer, Kathelijn, Gill, Joan C., P'Ng, Stephanie, Chowdary, Pratima, Escobar, Miguel A., Khayat, Claudia Djambas, Rusen, Luminita, Bensen-Kennedy, Debra, Blackman, Nicole, Limsakun, Tharin, Veldman, Alex, St. Ledger, Katie, Pabinger, Ingrid

“…Recombinant VIII (rVIII)-SingleChain is a novel B-domain–truncated recombinant factor VIII (rFVIII), comprised of covalently bonded factor VIII (FVIII) heavy…”
Get full text

Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation by Kreuz, Wolfhart, Gill, Joan C, Rothschild, Chantal, Manco-Johnson, Marilyn J, Lusher, Jeanne M, Kellermann, Elke, Gorina, Eduard, Larson, Peter J

“…The safety and efficacy of a full-length sucrose-formulated recombinant factor VIII product (rFVIII-FS; Kogenate FS; Kogenate Bayer) was evaluated in…”
Get more information

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease by Gill, Joan C., Castaman, Giancarlo, Windyga, Jerzy, Kouides, Peter, Ragni, Margaret, Leebeek, FrankW.G., Obermann-Slupetzky, Ortrun, Chapman, Miranda, Fritsch, Sandor, Pavlova, Borislava G., Presch, Isabella, Ewenstein, Bruce

“…This phase 3 trial evaluated the safety and hemostatic efficacy of a recombinant von Willebrand factor (rVWF) for treatment of bleeds in severe von Willebrand…”
Get full text

Hepatitis C Virus Induces Regulatory T Cells by Naturally Occurring Viral Variants to Suppress T Cell Responses by Cusick, Matthew F., Schiller, Jennifer J., Gill, Joan C., Eckels, David D.

“…Regulatory T cell markers are increased in chronically infected individuals with the hepatitis C virus (HCV), but to date, the induction and maintenance of…”
Get full text

Sustained high trough factor IX activity levels with continued use of rIX‐FP in adult and paediatric patients with haemophilia B by Gill, Joan C., Roberts, John, Li, Yanyan, Castaman, Giancarlo

Get full text

Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia by Ellery, Paul E. R., Hilden, Ida, Thyregod, Peter, Martinez, Nicholas D., Maroney, Susan A., Gill, Joan C., Mast, Alan E.

“…Introduction Tissue factor pathway inhibitor (TFPI) is a naturally occurring anticoagulant found in plasma, where it circulates bound to lipoproteins, factor V…”
Get full text

The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study by Kessler, Craig M, Friedman, Ken, Schwartz, Bruce A, Gill, Joan C, Powell, Jerry S

“…The pharmacokinetic (PK) profiles of von Willebrand factor (VWF) /factor VIII (FVIII) concentrates are important for treatment efficacy and safety of von…”
Get more information

Rituximab for treatment of inhibitors in haemophilia A. A Phase II study by Leissinger, C, Josephson, C D, Granger, S, Konkle, B A, Kruse-Jarres, R, Ragni, M V, Journeycake, J M, Valentino, L, Key, N S, Gill, J C, McCrae, K R, Neufeld, E J, Manno, C, Raffini, L, Saxena, K, Torres, M, Marder, V, Bennett, C M, Assmann, S F

“…The development of antibodies against infused factor VIII (FVIII) in patients with haemophilia A is a serious complication leading to poorly controlled…”
Get more information

Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcγRIIa and the integrin β3 cytoplasmic domain by Gao, Cunji, Boylan, Brian, Bougie, Dan, Gill, Joan C, Birenbaum, Jessica, Newman, Debra K, Aster, Richard H, Newman, Peter J

“…Thrombocytopenia and thrombosis following treatment with the integrin αIIbβ3 antagonist eptifibatide are rare complications caused by patient antibodies…”
Get full text

The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia by Gupta, Sweta, Siddiqi, Azfar‐E‐Alam, Soucie, J. Michael, Manco‐Johnson, Marilyn, Kulkarni, Roshni, Lane, Heidi, Ingram‐Rich, Robina, Gill, Joan C.

“…Summary This study prospectively compared the effect of secondary prophylaxis to episodic treatment on target joint (TJ) range of motion (ROM), number of joint…”
Get full text

Naturally occurring CD4+ T-cell epitope variants act as altered peptide ligands leading to impaired helper T-cell responses in hepatitis C virus infection by Cusick, Matthew F, Yang, Meiying, Gill, Joan C, Eckels, David D

“…Abstract Hepatitis C virus (HCV) has a high rate of replication and lacks RNA-proofreading capabilities, thereby leading to variant or mutant viruses…”
Get full text

Bleeding disorders: A common cause of menorrhagia in adolescents by Bevan, Jennifer A., Maloney, Kelly W., Hillery, Cheryl A., Gill, Joan C., Montgomery, Robert R., Scott, J.Paul

“…Objective: To determine the frequency of underlying bleeding disorders in adolescents with menorrhagia. Study design: We retrospectively reviewed the charts of…”
Get full text

Thromboelastography in the Assessment of Bleeding Following Surgery for Congenital Heart Disease by Niebler, Robert A., Gill, Joan C., Brabant, Christopher P., Mitchell, Michael E., Nugent, Melodee, Simpson, Pippa, Tweddell, James S., Ghanayem, Nancy S.

“…Background: Perioperative bleeding is common in pediatric cardiac surgery patients. Traditional laboratory tests do not adequately characterize coagulation…”
Get full text

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors by Key, N S, Aledort, L M, Beardsley, D, Cooper, H A, Davignon, G, Ewenstein, B M, Gilchrist, G S, Gill, J C, Glader, B, Hoots, W K, Kisker, C T, Lusher, J M, Rosenfield, C G, Shapiro, A D, Smith, H, Taft, E

“…To assess the safety and efficacy of a fixed dose of recombinant activated factor VII (rFVIIa; NovoSeven) in the home setting for mild to moderately severe…”
Get more information

Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models by Marek, Elizabeth, Momper, Jeremiah D, Hines, Ronald N, Takao, Cheryl M, Gill, Joan C, Pravica, Vera, Gaedigk, Andrea, Burckart, Gilbert J, Neville, Kathleen A

“…The objective of this study was to evaluate the performance of pediatric pharmacogenetic-based dose prediction models by using an independent cohort of…”
Get full text

Identification of FcγRIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human platelets by Boylan, Brian, Gao, Cunji, Rathore, Vipul, Gill, Joan C., Newman, Debra K., Newman, Peter J.

“…Immunoreceptor tyrosine-based activation motif (ITAM)–containing proteins have recently been demonstrated in macrophages and neutrophils to be required for…”
Get full text

Interferon-gamma secretion defects in haemophilia A patients receiving highly purified plasma-derived or recombinant factor VIII by Newton-Nash, D K, Tollerud, D, Guevarra, L, Gill, J C

“…The outcome of developing immune responses is influenced by interactions among a large and complex network of secreted cytokines. T-cell secretion of…”
Get more information

Epitopes of the NS3 protein of hepatitis C virus: Recognition in HLA-DR4 transgenic mice by Eckels, David D, Bian, Tonghua, Gill, Joan C, S⊘nderstrup, Grete

“…Hepatitis C virus (HCV) infects more than 180 million of the world's population and causes a persistent infection that over decades can result in cirrhosis and…”
Get full text

A study of prospective surveillance for inhibitors among persons with haemophilia in the United States by Soucie, J. M., Miller, C. H., Kelly, F. M., Payne, A. B., Creary, M., Bockenstedt, P. L., Kempton, C. L., Manco-Johnson, M. J., Neff, A. T.

“…Summary Inhibitors are a rare but serious complication of treatment of patients with haemophilia. Phase III clinical trials enrol too few patients to…”
Get full text

T-lymphocyte subpopulations in patients with classic hemophilia treated with cryoprecipitate and lyophilized concentrates by Menitove, J E, Aster, R H, Casper, J T, Lauer, S J, Gottschall, J L, Williams, J E, Gill, J C, Wheeler, D V, Piaskowski, V, Kirchner, P, Montgomery, R R

Get more information